GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
London, Jan 9, 2026, 10:50 GMT — Regular session GSK (GSK.L) shares were down 0.6% at 1,879.5 pence by 1050 GMT, trading in a 1,871p to 1,886p range. (London South East) The stock is still digesting a phase III win for bepirovirsen, GSK’s experimental chronic hepatitis B treatment, which the company says achieved a “functional cure” — meaning the virus can no longer be detected in blood tests for a sustained period after treatment. GSK said it plans to start global regulatory filings from the first quarter of 2026 and described bepirovirsen as an antisense oligonucleotide, a short strand of